Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry

Statin therapy is regarded as an effective medication to reduce cardiovascular events in patients at higher risk for future incidence of coronary artery disease. However, very few studies have been conducted to examine its implementation in non-Western real-world practice. In this study, we sought to describe statin prescription patterns in relation to patient characteristics in a Japanese multicenter percutaneous coronary intervention (PCI) registry as a foundation for quality improvement. We studied 15,024 patients that were prospectively enrolled in the Japan Cardiovascular Database-Keio interhospital Cardiovascular Study Registry from January 2009 to August 2014. The overall discharge statin non-prescription rate was 15.2%, without significant interhospital (MOR = 1.01) or annual differences (MOR = 1.13) observed. Hierarchical multivariable logistic regression analysis accounting for regional differences revealed that the presence of chronic kidney disease was associated with higher rates of statin non-prescription (OR 1.87, 95% confidence interval, 1.69–2.08, p value <0.001), and higher age (per 1-year increase) showed a trend for prescription of low-intensity statin (OR 1.00, 95% confidence interval, 1.00–1.01, p value = 0.045) within the subset of PCI patients (N = 4,853) enrolled after the year 2011. Our study indicates that patients with chronic kidney disease and elderlies may be the primary targets for maximizing the beneficial effect of statin therapy in post PCI patients.

[1]  J. Spertus,et al.  Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide , 2017, JAMA cardiology.

[2]  J. Knowles,et al.  Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease , 2017, JAMA cardiology.

[3]  Douglas K Owens,et al.  Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.

[4]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[5]  Zuoren Yu,et al.  Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk , 2016, Scientific Reports.

[6]  N. Wong,et al.  Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. , 2016, Journal of clinical lipidology.

[7]  B. Adhyaru,et al.  New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipid , 2016, Endocrinology and metabolism clinics of North America.

[8]  G. De Backer,et al.  Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. , 2016, Atherosclerosis.

[9]  C. Frei,et al.  Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). , 2016, The American journal of cardiology.

[10]  Sean M. O'Brien,et al.  2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures , 2016, Circulation. Cardiovascular quality and outcomes.

[11]  H. Miyata,et al.  An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS). , 2015, American heart journal.

[12]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[13]  Improve-It Investigators Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[14]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[15]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[16]  T. Ohkubo,et al.  Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study. , 2015, Journal of atherosclerosis and thrombosis.

[17]  Sandeep K. Krishnan,et al.  Statins in the Elderly: A Patient‐Focused Approach , 2015, Clinical cardiology.

[18]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[19]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[20]  J. K. Harrison,et al.  Invasive hemodynamic evaluation in patients with mechanical aortic valves. Catheterization and cardiovascular interventions: Official journal of the society for cardiac angiography & interventions 2013 , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[22]  N. Wong Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[23]  N. Kleiman,et al.  Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). , 2014, The American journal of cardiology.

[24]  Expert Panel on Dyslipidemia An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. , 2014, Atherosclerosis.

[25]  P. Barter International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. , 2014, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[26]  S. Kihara,et al.  The elderly. , 2014, Journal of atherosclerosis and thrombosis.

[27]  R. Hegele,et al.  Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. , 2013, The Canadian journal of cardiology.

[28]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[29]  Jane A. Linderbaum,et al.  2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[30]  Tetsuya Ohira,et al.  Cardiovascular disease epidemiology in Asia: an overview. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[31]  T. Uejima,et al.  Effects of statin treatment in patients with coronary artery disease and chronic kidney disease , 2013, Heart and Vessels.

[32]  T. Uejima,et al.  Recent characteristics and outcomes of Japanese stable angina pectoris after percutaneous coronary intervention. An observational cohort study using the Shinken Database. , 2013, International heart journal.

[33]  Jennifer G. Robinson,et al.  Heart Association Task Force on Practice Guidelines Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic , 2013 .

[34]  Takeshi Kimura,et al.  Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). , 2012, American Journal of Cardiology.

[35]  Takeshi Kimura,et al.  Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[36]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[37]  Deepak L. Bhatt,et al.  Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). , 2011, American heart journal.

[38]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[39]  Deepak L. Bhatt,et al.  Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). , 2010, American heart journal.

[40]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[41]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[42]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[43]  Makoto Watanabe,et al.  Cardiovascular Disease and Risk Factors in Asia: A Selected Review , 2008, Circulation.

[44]  J. Liao Safety and efficacy of statins in Asians. , 2007, The American journal of cardiology.

[45]  Hideo Tanaka,et al.  The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. , 2007, Atherosclerosis.

[46]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[47]  Michael Miller Intensive versus moderate lipid lowering with statins after acute coronary syndromes* , 2004, The New England journal of medicine.

[48]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[49]  E. DeLong Hierarchical modeling: its time has come. , 2003, American heart journal.

[50]  Peter C Austin,et al.  Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? , 2003, American heart journal.

[51]  北村 聖 "The New England Journal of Medicine". , 1962, British medical journal.